Tuning Pharmacokinetics and Biodistribution of a Targeted Drug Delivery System Through Incorporation of a Passive Targeting Component

Author(s): Kudgus RA, Walden CA, McGovern RM, Reid JM, Robertson JD, et al.

Abstract

Major challenges in the development of drug delivery systems (DDSs) have been the short half-life, poor bioavailability, insufficient accumulation and penetration of the DDSs into the tumor tissue. Understanding the pharmacokinetic (PK) parameters of the DDS is essential to overcome these challenges. Herein we investigate how surface chemistry affects the PK profile and organ distribution of a gold nanoparticle-based DDS containing both a passive and active targeting moiety via two common routes of administration: intravenous and intraperitoneal injections. Using LC/MS/MS, ELISA and INAA we report the half-life, peak plasma concentrations, area under the curve, ability to cross the peritoneal barrier and biodistribution of the nanoconjugates. The results highlight the design criteria for fine-tuning the PK parameters of a targeted drug delivery system that exploits the benefits of both active and passive targeting.

Similar Articles

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Author(s): Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al.

Survival and prognosis of patients with astrocytoma with atypical or anaplastic features

Author(s): Nelson D, Nelson J, Davis D, Chang C, Griffins T, et al.

Radium-223 in the treatment of osteoblastic metastases: a critical clinical review

Author(s): Humm JL, Sartor O, Parker C, Bruland OS, Macklis R

Alpha emitter radium-223 and survival in metastatic prostate cancer

Author(s): Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, et al.

Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis

Author(s): Bhattacharyya S, Bhattacharya R, Curley S, McNiven MA, Mukherjee P

Effect of nanoparticle surface charge at the plasma membrane and beyond

Author(s): Arvizo RR, Miranda OR, Thompson MA, Pabelick CM, Bhattacharya R, et al.

Modulating Pharmacokinetics, Tumor Uptake and Biodistribution by Engineered Nanoparticles

Author(s): Arvizo RR, Miranda OR, Moyano DF, Walden CA, Giri K, et al.

Switching the Targeting Pathways of a Therapeutic Antibody by Nanodesign

Author(s): Bhattacharyya S, Singh RD, Pagano R, Robertson JD, Bhattacharya R, et al.

Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors

Author(s): Kennel SJ, Chappell LL, Dadachova K, Brechbiel MW, Lankford TK, et al.

LnPO4 nanoparticles doped with Ac-225 and sequestered daughters for targeted alpha therapy

Author(s): McLaughlin MF, Robertson D, Pevsner PH, Wall JS, Mirzadeh S, et al.

LaPO4 Nanoparticles Doped with Actinium-225 that Partially Sequester Daughter Radionuclides

Author(s): Woodward J, Kennel SJ, Stuckey A, Osborne D, Wall J, et al.

Gold Coated Lanthanide Phosphate Nanoparticles for Targeted Alpha Generator Radiotherapy

Author(s): McLaughlin MF, Woodward J, Boll RA, Wall JS, Rondinone AJ, et al.

Bioelectric effects of intense ultrashort pulses

Author(s): Joshi RP, Schoenbach KH

Nanosecond pulsed electric field thresholds for nanopore formation in neural cells

Author(s): Roth CC, Tolstykh GP, Payne JA, Kuipers MA, Thompson GL